Pancreatic ductal carcinoma is one of the most lethal malignancies, but in recent years a number of positive developments have occurred in the management of pancreatic carcinoma. This article aims to give an overview of the current knowledge regarding the role of radiotherapy in the treatment of pancreatic ductal adenocarcinoma (PDAC). The results of meta-analyses, phase III-studies, and phase II-studies using chemoradiotherapy and chemotherapy for resectable and non-resectable PDAC were reviewed. The use of radiotherapy is discussed in the neoadjuvant and adjuvant settings as well as in the locally advanced situation. Whenever possible, radiotherapy should be performed as simultaneous chemoradiotherapy. Patients with PDAC should be offered...
Treatment of pancreatic ductal adenocarcinoma (PDAC) is increasingly multidisciplinary, with neoadju...
Treatment of pancreatic ductal adenocarcinoma (PDAC) is increasingly multidisciplinary, with neoadju...
Treatment of pancreatic ductal adenocarcinoma (PDAC) is increasingly multidisciplinary, with neoadju...
Abstract Pancreatic ductal carcinoma is one of the most lethal malignancies, but in recent years a n...
Pancreatic cancer is one of the most aggressive human tumors and the incidence has increased over th...
We aimed to demonstrate a single institution experience of treatment of pancreatic ductal carcinoma ...
Abstract Despite combination chemotherapy demonstrating a positive effect on survival, the clinical ...
[[abstract]]Despite combination chemotherapy demonstrating a positive effect on survival, the clinic...
International audienceAt diagnosis, about 15% of patients with pancreatic cancer present with a rese...
International audienceAt diagnosis, about 15% of patients with pancreatic cancer present with a rese...
AbstractPancreatic carcinoma is a malignancy with a poor prognosis and the 4th. most common cause of...
Introduction: Of all the carcinomas, pancreatic carcinoma (PC) has the highest mortality rate, with ...
Introduction: Of all the carcinomas, pancreatic carcinoma (PC) has the highest mortality rate, with ...
A small number of patients exist with carcinoma of the pancreas with an inoperable but not metastasi...
The overall survival of patients with resectable or borderline-resectable pancreatic ductal adenocar...
Treatment of pancreatic ductal adenocarcinoma (PDAC) is increasingly multidisciplinary, with neoadju...
Treatment of pancreatic ductal adenocarcinoma (PDAC) is increasingly multidisciplinary, with neoadju...
Treatment of pancreatic ductal adenocarcinoma (PDAC) is increasingly multidisciplinary, with neoadju...
Abstract Pancreatic ductal carcinoma is one of the most lethal malignancies, but in recent years a n...
Pancreatic cancer is one of the most aggressive human tumors and the incidence has increased over th...
We aimed to demonstrate a single institution experience of treatment of pancreatic ductal carcinoma ...
Abstract Despite combination chemotherapy demonstrating a positive effect on survival, the clinical ...
[[abstract]]Despite combination chemotherapy demonstrating a positive effect on survival, the clinic...
International audienceAt diagnosis, about 15% of patients with pancreatic cancer present with a rese...
International audienceAt diagnosis, about 15% of patients with pancreatic cancer present with a rese...
AbstractPancreatic carcinoma is a malignancy with a poor prognosis and the 4th. most common cause of...
Introduction: Of all the carcinomas, pancreatic carcinoma (PC) has the highest mortality rate, with ...
Introduction: Of all the carcinomas, pancreatic carcinoma (PC) has the highest mortality rate, with ...
A small number of patients exist with carcinoma of the pancreas with an inoperable but not metastasi...
The overall survival of patients with resectable or borderline-resectable pancreatic ductal adenocar...
Treatment of pancreatic ductal adenocarcinoma (PDAC) is increasingly multidisciplinary, with neoadju...
Treatment of pancreatic ductal adenocarcinoma (PDAC) is increasingly multidisciplinary, with neoadju...
Treatment of pancreatic ductal adenocarcinoma (PDAC) is increasingly multidisciplinary, with neoadju...